HIM
ITCI

Hillsdale Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Hillsdale Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-90
Closed -$6.16K – 714
2024
Q2 		$6.16K Buy
90
+10
+13% +$694 ﹤0.01% 534
2024
Q1 		$5.54K Hold
80
– – ﹤0.01% 564
2023
Q4 		$5.73K Sell
80
-50,620
-100% -$2.91M ﹤0.01% 515
2023
Q3 		$2.64M Buy
50,700
+2,240
+5% +$130K 0.24% 153
2023
Q2 		$3.07M Sell
48,460
-36,140
-43% -$2.25M 0.28% 141
2023
Q1 		$4.58M Sell
84,600
-11,300
-12% -$546K 0.39% 89
2022
Q4 		$5.08M Buy
95,900
+1,900
+2% +$95.2K 0.43% 66
2022
Q3 		$4.37M Buy
94,000
+79,900
+567% +$4.17M 0.4% 89
2022
Q2 		$805K Buy
+14,100
New +$799K 0.06% 212

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hillsdale Investment Management's ITCI Position: Q3 2024 in Review

Hillsdale Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 90 shares — an estimated $6.16K sold.

Hillsdale Investment Management first reported a position in ITCI in Q2 2022 and held it in 9 quarters. The position peaked at $5.08M in Q4 2022. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Hillsdale Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Hillsdale Investment Management sold 90 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $6.16K.
  • Hillsdale Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 9 quarters.
  • Hillsdale Investment Management's Intra-Cellular Therapies Inc. position peaked at $5.08M in Q4 2022.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Hillsdale Investment Management's 13F filing for Q3 2024, filed 12 Nov 2024.